Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Part of paid clinical trials in Duarte, California.

Sponsor
City of Hope Medical Center
Study ID
NCT00182650
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • aldesleukin — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • therapeutic autologous lymphocytes — BIOLOGICAL
  • fludarabine phosphate — DRUG

Study Details

RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop cancer cells from growing. Rituximab and fludarabine may also prevent the body from making an immune response against the laboratory-treated white blood cells that are put back into the body. Interleukin-2 may help the laboratory-treated white blood cells stay in the body longer. Giving cellular adoptive immunotherapy together with rituximab, fludarabine, and interleukin-2 may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy in treating patients with relapsed or refractory follicular non-Hodgkin's lymphoma.

Key Dates

Start date
Jun 30, 2004
Status verified
Dec 2009
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008

Study Design

Enrollment
5 participants (estimated)
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010-3000-

Find similar trials in Duarte, CA

By research site
City of Hope Comprehensive Cancer Center· Duarte, CA

Related Studies